• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续的 4-1BB 共刺激信号对于过继性 T 细胞治疗中肿瘤浸润淋巴细胞的最佳扩增是必需的。

Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy.

机构信息

Department of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA ; The Immunology Program of the University of Texas Health Science Center, Graduate School of Biomedical Sciences; The University of Texas MD Anderson Cancer Center; Houston, TX USA.

出版信息

Oncoimmunology. 2013 Sep 1;2(9):e25581. doi: 10.4161/onci.25581. Epub 2013 Jul 3.

DOI:10.4161/onci.25581
PMID:24319633
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3850170/
Abstract

Co-stimulation through members of the tumor necrosis factor receptor (TNFR) family appears to be critical for the generation of T cells with optimal effector-memory properties for adoptive cell therapy. Our work suggests that continuous 4-1BB/CD137 co-stimulation is required for the expansion of T cells with an optimal therapeutic profile and that the administration of 4-1BB agonists upon adoptive cell transfer further improves antitumor T-cell functions.

摘要

肿瘤坏死因子受体 (TNFR) 家族成员的共刺激似乎对于产生具有最佳效应记忆特性的 T 细胞用于过继细胞治疗至关重要。我们的工作表明,持续的 4-1BB/CD137 共刺激对于扩增具有最佳治疗谱的 T 细胞是必需的,并且在过继细胞转移时给予 4-1BB 激动剂进一步改善了抗肿瘤 T 细胞功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a92e/3850170/eafe4c7b3047/onci-2-e25581-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a92e/3850170/eafe4c7b3047/onci-2-e25581-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a92e/3850170/eafe4c7b3047/onci-2-e25581-g1.jpg

相似文献

1
Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy.持续的 4-1BB 共刺激信号对于过继性 T 细胞治疗中肿瘤浸润淋巴细胞的最佳扩增是必需的。
Oncoimmunology. 2013 Sep 1;2(9):e25581. doi: 10.4161/onci.25581. Epub 2013 Jul 3.
2
Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.4-1BB/CD137 共刺激可改善过继性 T 细胞治疗中 CD8(+)黑色素瘤肿瘤浸润淋巴细胞的扩增和功能。
PLoS One. 2013;8(4):e60031. doi: 10.1371/journal.pone.0060031. Epub 2013 Apr 1.
3
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.CD137/4-1BB 通路共刺激可保护人黑色素瘤肿瘤浸润淋巴细胞免于激活诱导的细胞死亡,并增强抗肿瘤效应功能。
J Immunother. 2011 Apr;34(3):236-50. doi: 10.1097/CJI.0b013e318209e7ec.
4
Triggering co-stimulation directly in melanoma tumor fragments drives CD8 tumor-infiltrating lymphocyte expansion with improved effector-memory properties.直接在黑色素瘤肿瘤片段中触发共刺激可驱动CD8肿瘤浸润淋巴细胞扩增,并改善效应记忆特性。
Oncoimmunology. 2015 Jul 1;4(12):e1040219. doi: 10.1080/2162402X.2015.1040219. eCollection 2015 Dec.
5
Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.CD137(4-1BB)共刺激后线粒体形态和功能的重编程。
Cancer Immunol Res. 2018 Jul;6(7):798-811. doi: 10.1158/2326-6066.CIR-17-0767. Epub 2018 Apr 20.
6
Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.体外操控肿瘤微环境以增强肿瘤浸润淋巴细胞的扩增用于过继性细胞治疗。
Clin Cancer Res. 2015 Feb 1;21(3):611-21. doi: 10.1158/1078-0432.CCR-14-1934. Epub 2014 Dec 3.
7
Finding a needle in a haystack: Activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients.大海捞针:激活诱导的CD137表达可准确识别癌症患者体内天然存在的肿瘤反应性T细胞。
Oncoimmunology. 2013 Dec 1;2(12):e27184. doi: 10.4161/onci.27184. Epub 2013 Dec 9.
8
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.4-1BB激动剂:肿瘤免疫的多能增强剂。
Front Oncol. 2015 Jun 8;5:117. doi: 10.3389/fonc.2015.00117. eCollection 2015.
9
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.通过激动型抗CD137单克隆抗体聚焦并维持抗肿瘤CTL效应性杀伤反应。
Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7551-6. doi: 10.1073/pnas.1506357112. Epub 2015 Jun 1.
10
Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.基于CD137分离选择用于过继性细胞治疗的共享和新抗原反应性T细胞。
Front Immunol. 2017 Oct 10;8:1211. doi: 10.3389/fimmu.2017.01211. eCollection 2017.

引用本文的文献

1
Current developments in T-cell receptor therapy for acute myeloid leukemia.急性髓系白血病T细胞受体疗法的当前进展
Blood Adv. 2025 Jun 24;9(12):3069-3089. doi: 10.1182/bloodadvances.2024014105.
2
Biomaterials for enhanced immunotherapy.用于增强免疫疗法的生物材料。
APL Bioeng. 2022 Dec 16;6(4):041502. doi: 10.1063/5.0125692. eCollection 2022 Dec.
3
Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.针对癌症和自身免疫性疾病中 CD95L/CD95 信号的治疗方法。

本文引用的文献

1
Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.4-1BB/CD137 共刺激可改善过继性 T 细胞治疗中 CD8(+)黑色素瘤肿瘤浸润淋巴细胞的扩增和功能。
PLoS One. 2013;8(4):e60031. doi: 10.1371/journal.pone.0060031. Epub 2013 Apr 1.
2
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.特异性淋巴细胞亚群预测转移性黑色素瘤患者接受扩增自体肿瘤浸润淋巴细胞过继细胞治疗的反应。
Clin Cancer Res. 2012 Dec 15;18(24):6758-70. doi: 10.1158/1078-0432.CCR-12-1177. Epub 2012 Oct 2.
3
Cell Death Dis. 2022 Mar 17;13(3):248. doi: 10.1038/s41419-022-04688-x.
4
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.可溶性 CD137 作为一种动态生物标志物,用于监测激动型 CD137 免疫疗法。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-003532.
5
Switchable immune modulator for tumor-specific activation of anticancer immunity.用于肿瘤特异性激活抗癌免疫的可切换免疫调节剂。
Sci Adv. 2021 Sep 10;7(37):eabg7291. doi: 10.1126/sciadv.abg7291.
6
The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models.HPV16mE7脉冲和SOCS1沉默的树突状细胞增强的CAR-T-PD1细胞在宫颈癌模型中的抗肿瘤活性
Cancer Manag Res. 2021 Aug 4;13:6045-6053. doi: 10.2147/CMAR.S321402. eCollection 2021.
7
Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy.免疫检查点阻断以改善用于过继性细胞疗法的肿瘤浸润淋巴细胞。
PLoS One. 2016 Apr 6;11(4):e0153053. doi: 10.1371/journal.pone.0153053. eCollection 2016.
8
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.使用睡美人转座子/转座酶系统稳定、非病毒表达突变的肿瘤新抗原特异性T细胞受体
Mol Ther. 2016 Jun;24(6):1078-1089. doi: 10.1038/mt.2016.51. Epub 2016 Mar 5.
9
Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.用于治疗转移性癌症的肿瘤浸润淋巴细胞。
Mol Oncol. 2015 Dec;9(10):1918-35. doi: 10.1016/j.molonc.2015.10.018. Epub 2015 Oct 30.
10
Trial Watch: Adoptive cell transfer for oncological indications.试验观察:用于肿瘤适应症的过继性细胞转移
Oncoimmunology. 2015 May 5;4(11):e1046673. doi: 10.1080/2162402X.2015.1046673. eCollection 2015 Nov.
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
采用 T 细胞转移免疫疗法治疗转移性黑色素瘤的大量预处理患者中持久的完全应答。
Clin Cancer Res. 2011 Jul 1;17(13):4550-7. doi: 10.1158/1078-0432.CCR-11-0116. Epub 2011 Apr 15.
4
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.CD137/4-1BB 通路共刺激可保护人黑色素瘤肿瘤浸润淋巴细胞免于激活诱导的细胞死亡,并增强抗肿瘤效应功能。
J Immunother. 2011 Apr;34(3):236-50. doi: 10.1097/CJI.0b013e318209e7ec.
5
4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes.4-1BB 介导的扩增可更好地检测黑色素瘤前哨淋巴结中体内初始效应记忆 CD8+T 细胞。
Clin Immunol. 2010 Nov;137(2):221-33. doi: 10.1016/j.clim.2010.07.009. Epub 2010 Aug 13.
6
MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.MART-1 特异性黑色素瘤肿瘤浸润淋巴细胞在体外抗原再刺激后保持 CD28 表达,具有改善的存活和扩增能力。
J Immunol. 2010 Jan 1;184(1):452-65. doi: 10.4049/jimmunol.0901101. Epub 2009 Nov 30.
7
4-1BBL costimulation retrieves CD28 expression in activated T cells.4-1BBL共刺激可恢复活化T细胞中CD28的表达。
Cell Immunol. 2009;256(1-2):39-46. doi: 10.1016/j.cellimm.2009.01.003. Epub 2009 Feb 12.
8
TNF/TNFR family members in costimulation of T cell responses.肿瘤坏死因子/肿瘤坏死因子受体家族成员在T细胞反应共刺激中的作用
Annu Rev Immunol. 2005;23:23-68. doi: 10.1146/annurev.immunol.23.021704.115839.
9
A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo.在体内原发性与继发性CD8 T细胞对流感的反应过程中,共刺激从CD28向4-1BB的转变。
J Immunol. 2004 Jan 15;172(2):981-8. doi: 10.4049/jimmunol.172.2.981.
10
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.用于黑色素瘤患者过继性转移治疗的肿瘤浸润淋巴细胞培养物的生成。
J Immunother. 2003 Jul-Aug;26(4):332-42. doi: 10.1097/00002371-200307000-00005.